Premarin Vaginal Cream

Atrophic vaginitis, dyspareunia & kraurosis vulvae.

Intravag Atrophic vaginitis & kraurosis vulvae Initially 0.5 g in cyclic regimen (daily for 21 days & then off for 7 days), may be adjusted to 2 g. Dyspareunia 0.5 g twice wkly administered in continuous or cyclic regimen (daily for 21 days & then off for 7 days).

Hypersensitivity. Undiagnosed abnormal uterine bleeding. Known, suspected or history of breast cancer; estrogen-dependent neoplasia; thrombophilic disorders. Active or history of confirmed arterial thromboembolic disease or VTE. Active or chronic hepatic dysfunction or disease. Known or suspected pregnancy.

Discontinue use if stroke or VTE occur or suspected; visual abnormalities develop. Not to be used for prevention of CV disease or dementia. Increased risk of MI, pulmonary embolism, invasive breast & ovarian cancer; CV risk, DVT; endometrial, breast & ovarian cancer; dementia; gallbladder disease; hyper- or hypocalcemia; angioedema; fluid retention, cardiac dysfunction; preexisting hypertriglyceridemia; elevated BP; exacerbation of asthma, epilepsy, migraine w/ or w/o aura, otosclerosis, porphyria, SLE, hepatic hemangiomas, endometriosis; hypothyroidism; impaired glucose tolerance. Systemic absorption. Discontinue at least 4-6 wk before surgery of type associated w/ increased risk of thromboembolism or during prolonged immobilization. Concurrent use w/ latex. History of cholestatic jaundice, hepatic impairment. Renal dysfunction. Not to be used during pregnancy & lactation. Not to be used in childn. Elderly ≥65 yr.

Vaginitis including vag candidiasis, cystitis-like syndrome; breast, ovarian & endometrial cancer, fibrocystic breast changes, hepatic hemangiomas enlargement, benign meningioma growth potentiation; urticaria, angioedema, hypersensitivity, anaphylactic/anaphylactoid reactions; precocious puberty; glucose intolerance, hypocalcemia; changes in libido, mood disturbances, irritability, depression, dementia; dizziness, headache, migraine, nervousness, CVA/stroke, chorea exacerbation; intolerance to contact lenses, retinal vascular thrombosis; MI; pulmonary embolism, venous thrombosis; nausea, vomiting, bloating, abdominal pain, pancreatitis, ischemic colitis; gallbladder disease, cholestatic jaundice; alopecia, chloasma/melasma, hirsutism, pruritus, rash, erythema multiforme & nodosum; arthralgia, leg cramps; breakthrough bleeding/spotting, dysmenorrhea/pelvic pain, breast pain, tenderness, enlargement & discharge, vulvovag discomfort eg, burning, irritation & genital pruritus, vag discharge, leucorrhea, gynecomastia in males, increased size of uterine leiomyomata, endometrial hyperplasia; edema; increased/decreased wt, increased triglycerides & BP.

Reduced plasma conc w/ CYP3A4 inducers eg, St. John's wort prep, phenobarb, phenytoin, carbamazepine, rifampicin, dexamethasone. Increased plasma conc w/ CYP3A4 inhibitors eg, cimetidine, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice. Interference w/ lab & other diagnostic tests.

Preparations for Vaginal Conditions

G03CA57 - conjugated estrogens ; Belongs to the class of natural and semisynthetic estrogens used in estrogenic hormone preparations.

C